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Cerebral Gaseous Microemboli are Detectable During
Continuous Venovenous Hemodialysis in Critically Ill
Patients: An Observational Pilot Study
Gabor Erdoes, MD,*w Clemens Kietaibl, MD,* Stefan Boehme, MD,* Roman Ullrich, MD,*
Klaus Markstaller, MD,* Balthasar Eberle, MD,w and Klaus U. Klein, MD*
Background: Continuous venovenous hemodialysis (CVVHD)
may generate microemboli that cross the pulmonary circulation
and reach the brain. The aim of the present study was to
quantify (load per time interval) and qualify (gaseous vs. solid)
cerebral microemboli (CME), detected as high-intensity tran-
sient signals, using transcranial Doppler ultrasound.
Materials and Methods: Twenty intensive care unit (ICU group)
patients requiring CVVHD were examined. CME were recorded
in both middle cerebral arteries for 30 minutes during CVVHD
and a CVVHD-free interval. Twenty additional patients, hos-
pitalized for orthopedic surgery, served as a non-ICU control
group. Statistical analyses were performed using the Mann-
Whitney U test or the Wilcoxon matched-pairs signed-rank test,
followed by Bonferroni corrections for multiple comparisons.
Results: In the non-ICU group, 48 (14.5-169.5) (median [range])
gaseous CME were detected. In the ICU group, the 67.5 (14.5-
588.5) gaseous CME detected during the CVVHD-free interval
increased 5-fold to 344.5 (59-1019) during CVVHD (P<0.001).
The number of solid CME was low in all groups (non-ICU
group: 2 [0-5.5]; ICU group CVVHD-free interval: 1.5 [0-14.25];
ICU group during CVVHD: 7 [3-27.75]).
Conclusions: This observational pilot study shows that CVVHD
was associated with a higher gaseous but not solid CME burden
in critically ill patients. Although the diﬀerentiation between
gaseous and solid CME remains challenging, our ﬁnding may
support the hypothesis of microbubble generation in the
CVVHD circuit and its transpulmonary translocation toward
the intracranial circulation. Importantly, the impact of gaseous
and solid CME generated during CVVHD on brain integrity of
critically ill patients currently remains unknown and is highly
debated.
Key Words: transcranial Doppler ultrasound, high-intensity
transient signals, continuous venovenous hemodialysis, cerebral
microemboli
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As far back as 1975 it was postulated that in patientsundergoing hemodialysis, microemboli are generated
that enter the pulmonary circulation and cause pulmo-
nary inﬂammation and injury.1 Subsequently, the pres-
ence of microemboli has been repeatedly demonstrated
downstream of the arteriovenous ﬁstula, the subclavian
vein, and the venous air trap and outlet line of the he-
modialysis circuit.2–7 Microemboli that enter the car-
diovascular system can cause deleterious eﬀects in the
lungs and remote organs, including microembolization as
well as activation of coagulation, complement, leuko-
cytes, and platelets.8 Importantly, the burden of micro-
emboli that forms during chronic hemodialysis appears
signiﬁcant, with potentially >500 microemboli per mi-
nute generated in the hemodialysis circuit, which may
bypass the air trap and enter the venous circulation.7
Recent research suggested that the microemboli that
develop during hemodialysis may pass through the lung
barrier and that they can be detected in the carotid artery
using Doppler ultrasound scanning.9 It seems possible
that microemboli may cause injury to remote organs such
as the brain. Patients with chronic kidney disease that
require hemodialysis experience worse cognitive outcomes
than age-matched and sex-matched control individuals,
supporting the possibility that microemboli may con-
tribute to brain dysfunction.10 Like solid microemboli,
gaseous microemboli that form into larger gaseous bub-
bles can cause capillary occlusion and hypoxia down-
stream of the blockade. According to the Epstein-Plesset
model, the dissolution time for a 1mm3 air bubble is in
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the range of 11 to 70 days, highlighting the potential
danger of gaseous microemboli.8 Modern transcranial
Doppler ultrasound (TCD) allows for the detection and
diﬀerentiation of high-intensity transient signals (HITS)
in both middle cerebral arteries (MCAs) into artefacts,
solid, and gaseous cerebral microemboli (CME) with high
accuracy. Emboli diﬀerentiation is based on the fact that
solid microemboli reﬂect ultrasound at lower frequencies
and decibel ranges compared with gaseous microemboli.11
However, there are currently no published articles re-
porting CME counts in critically ill patients undergoing
continuous venovenous hemodialysis (CVVHD).
The aim of the present study was to use multi-
frequency pulsed TCD to both quantify (count per
30min) and characterize (gaseous vs. solid) CME in both
MCAs in intensive care unit (ICU) patients during run-
ning and connected (activated) CVVHD and during a
CVVHD-free interval. We hypothesized that gaseous and
solid CME counts would increase during activated
CVVHD as compared with those during CVVHD-free
interval. In addition, TCD measurements were performed
in hospitalized orthopedic patients without CVVHD
therapy that served as a non-ICU control group.
MATERIALS AND METHODS
Study Design
This study included an ICU group and a non-ICU
group. For the ICU group, the study design was a single-
center, prospective, observational, pilot clinical trial. The
research was conducted in agreement with the Declara-
tion of Helsinki. Ethical approval was provided by the
Ethics Committee of the Medical University of Vienna,
Austria (No. 1706/2013, Chair: E. Singer) on September
30, 2013. The study was registered with the United States
National Institutes of Health (US NIH, Clinical-
Trials.gov #NCT02021045) in November 2013. All pro-
cedures were performed at the Medical University of
Vienna between September 2013 and January 2014 after
obtaining written patient informed consent. The patient
cohort consisted of awake and sedated ICU patients
(n=20) aged between 18 and 90 years undergoing
CVVHD. The study inclusion criterion was CVVHD re-
nal replacement therapy performed in the in-house ICU.
The study exclusion criteria were having a preexisting
neurological morbidity, neurocognitive disturbances,
carotid artery stenosis >70%, medical history of patent
foramen ovale, treatment with other extracorporeal de-
vices (such as extracorporeal membrane oxygenation),
cardiac pathologies (valvular heart disease, endocarditis),
pregnancy, drug abuse, an allergy to any materials con-
tained in the medical device used in the study, or temporal
skin/bone lesions.
The non-ICU group was added post hoc because
the ICU group showed signiﬁcant gaseous CME counts
during the CVVHD-free time interval. This control group
consisted of non-ICU patients from another ongoing
clinical study (the ﬁrst 20 consecutive patients with bi-
lateral TCD signals) that were included in our data
analysis to allow us a better interpretation of the ﬁndings
in the ICU population. This second study was a single-
center, prospective, observational, clinical trial. The re-
search was conducted in agreement with the Declaration
of Helsinki. Ethical approval was provided by the Ethics
Committee of the Medical University of Vienna, Austria
(No. 1633/2013, Chair: E. Singer) on September 09, 2013.
The study was registered with the US NIH (Clinical-
Trials.gov #NCT02340416) in January 2015. All proce-
dures were performed at the Medical University of
Vienna between August 2014 and November 2014 after
obtaining written patient informed consent. The patient
cohort consisted of awake patients aged between 50 and
90 years, undergoing a baseline TCD examination before
elective orthopedic surgery (n=20). The study inclusion
criteria were implantation of a hip/knee/shoulder pros-
thesis, or spinal surgery. The study exclusion criteria were
presence of a severe valvular heart defect or an acute
neurological disorder.
Protocol
The ICU group patients were enrolled in the study
by G.E. or K.U.K. in chronological order, according to
their initiation of CVVHD in the ICU. All patients were
subject to standard ICU monitoring (Dra¨ger Inﬁnity
Delta, Lu¨beck, Germany). All patients were placed in the
routine ICU positioning supine with 30-degree elevation
of the head. All patients received standard ICU treatment
according to the individual patient needs. All lines from
and to the patients were checked for correct closed con-
nections and correct placement. Each patient was meas-
ured ﬁrst during CVVHD therapy for 30 minutes and
thereafter during the CVVHD-free interval for 30
minutes. The study protocol required stopping of the
CVVHD therapy and disconnecting the circuit tubing
connections, therefore, a recovery period of 30 minutes
was maintained between both TCD examinations. No
other interventions including drug injections, line ﬂush-
ing, changing the perfusor infusion rate, changing the
respirator setting, body or head movement or any other
treatments were permitted during the examinations. For
the non-ICU group, 20 awake, hospitalized orthopedic
patients not undergoing CVVHD were monitored using
the same TCD technology during a TCD baseline ex-
amination for a duration of 15 minutes, with data nor-
malized for 30 minutes, before orthopedic surgery
(performed by C.K. and K.U.K). All patients were sub-
ject to standard operation room monitoring (Dra¨ger In-
ﬁnity Delta). Likewise, patients were placed supine with
30-degree elevation of the head and no interventions
(including drug injections, line ﬂushing, changing the
infusion rate, blood infusion, and therapeutic manipu-
lations) were permitted during the TCD examinations.
CVVHD Therapy
ICU group CVVHD was performed using multi-
Filtrate (Fresenius Medical Care Deutschland GmbH,
Bad Homburg, Germany) according to the manu-
facturer’s speciﬁcations. The hemodialysis setup included
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an Ultraﬂux AV1000S hemoﬁlter, a hemoﬁltration sol-
ution (Ci-Ca dialysate K2 solution), and a high-ﬂow lu-
men catheter (14Fr, 15 cm) for central venous access
(Teleﬂex Medical; Arrow, NC). Regional anticoagulation
was achieved by preﬁlter infusion of citrate (CiCa) with a
target citrate concentration of 3 to 5mmol/L in the ﬁlter
and a postﬁlter concentration of ionized calcium between
0.2 and 0.4mmol/L. The multiFiltrate was equipped with
a regular air trap and detector using the ultrasound
principle (LP 450-3). Although the blood ﬂow (80 to
120mL/min) and dialysate ﬂow (1500 to 4000mL/min) of
the CVVHD machine were individually set, each setting
remained constant during both TCD measurements.
Multifrequency Pulsed TCD Ultrasound
This study used multifrequency pulsed TCD
technology for the real-time detection and diﬀerentiation
of HITS into artifacts, solid CME, and gaseous CME
(Doppler BoxX; Compumedics Germany GmbH, DWL,
Singen, Germany). The software is based on the algo-
rithm described by Devuyst and colleagues and uses 4
speciﬁc features for the diﬀerentiation of artefact and
solid and gaseous CME: the time delay, the peak
frequency, the relative power, and the symmetry of the
signal envelope.12–20 Measurements were performed by 2
investigators (G.E. and K.U.K.) according to the guide-
lines set by the International Consensus Group on HITS
detection.21 The preparation for the TCD examination
requires an average of 15 to 30 minutes to mount the head
frame and to locate the optimum bone window area. A
size-adjustable probe holder was mounted bilaterally over
the temporal bone window for 2.0 and 2.5MHz MCAs
insonation at 55 to 70mm depth with a sample volume
length of 8mm (DiaMon; Compumedics Germany
GmbH). The pulse repetition frequency was set at 7 kHz
and the detection threshold for HITS was adjusted to
9 dB.21 Power output and gain settings were adjusted
to provide an optimal signal-to-noise ratio. Doppler
velocity and power M-mode spectrograms were recorded
and the fast Fourier transform size was set at 100Hz
to allow for real-time signal detection and diﬀerentiation
(Fig. 1).11
Statistics
Data were analyzed for normality distribution using
the Shapiro-Wilk test. The Mann-Whitney U test was
used to test for diﬀerences between the ICU and non-ICU
control groups, followed by the Bonferroni method for
multiple comparisons (P<0.05). The Wilcoxon matched-
pairs signed-rank test was used to detect diﬀerences be-
tween CVVHD and the CVVHD-free interval, followed
by the Bonferroni method for multiple comparisons
(P<0.05). All data are presented as median and inter-
quartile range (25% to 75% percentile). GraphPad Prism
Version 6.0 was used for all data analyses and to produce
box and whisker plots (Tukey) and staggered outliers
(GraphPad Software, La Jolla, CA).
RESULTS
Patient Characteristics
In total, 29 ICU patients were enrolled in the study,
and 20 patients (6 females and 14 males, aged 29 to 75 y)
were included in the ﬁnal analysis (Table 1). TCD meas-
urements could not be performed in 5 patients because of
the absence of a temporal bone window, and 4 patients
were excluded from the ﬁnal analysis because of pre-
mature TCD signal loss due to agitation. CVVHD was
initiated because of electrolyte and metabolic dis-
turbances (n=15), volume overload and concomitant
respiratory failure (n=3), or acute kidney failure (n=2).
Twenty-ﬁve awake, non-ICU control patients scheduled
for orthopedic surgery (TCD examination shortly before
surgery) were enrolled in the study; the ﬁrst consecutive
20 patients (12 female, 8 male; aged 51 to 83 y) with knee
surgery (n=7), hip surgery (n=9), and spine and
shoulder surgery (each n=2) were included in the ﬁnal
analysis. Five patients were excluded because of the ab-
sence of a temporal bone window.
Gaseous and Solid CME
In the non-ICU group, 48 (14.5 to 169.5) gaseous
CME were detected. In the ICU group, there were 67.5
(14.5 to 588.5) gaseous CME during the CVVHD-free
interval and 344.5 (59 to 1019) during CVVHD (Fig. 2). A
signiﬁcant diﬀerence in gaseous CME counts was detected
between the non-ICU control group and the ICU group
during CVVHD (P=0.041) and within the ICU group
between CVVHD and CVVHD-free interval (P<0.001).
No diﬀerences in gaseous CME counts were detected
between the non-ICU control group and the ICU group
during the CVVHD-free interval. Solid CME were low
in number and showed a skewed distribution in all
groups (non-ICU control group: 2 [0 to 5.5]; ICU group
CVVHD-free interval: 1.5 [0 to 14.25]; and ICU group
during CVVHD: 7 [3 to 27.75]). A signiﬁcant diﬀerence
was only observed between the non-ICU control group
and the ICU group during CVVHD therapy (P=0.033).
DISCUSSION
In this observational pilot study, multifrequency
pulsed TCD technology was used to quantify (count per
30min) and qualify (gaseous vs. solid) CME in both
MCAs in an ICU group during CVVHD and during a
CVVHD-free interval; and in a non-ICU control group
of hospitalized orthopedic patients. These study results
showed that (a) critically ill patients experience >5-fold
increase in gaseous but not solid CME counts during
activated CVVHD as compared with those during
CVVHD-free interval; and (b) also the non-ICU control
group showed a signiﬁcant gaseous CME count.
Origin, Composition, and Transmission of
Microemboli
Numerous in vitro and in vivo studies have con-
ﬁrmed that microemboli are generated in hemodialysis
systems that pass through the bubble detection system
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without triggering an alarm.2–7 Microemboli caused by
hemodialysis are composed of ﬁbrinogen, artiﬁcial ma-
terials, or air bubbles.8 It has been suggested that the
majority of microemboli are gaseous in nature based on
experimental studies demonstrating that microemboli
were still detected in hemodialysis circuits when dextran
was used instead of whole blood.22 Microemboli that
enter the venous circulation reach the lungs and were
thought to be ﬁltered in the 5 to 8 mm diameter pulmonary
capillaries. However, several studies have demonstrated
that microemboli can pass the heart or lungs and cause
arterial embolism.8 Notably, 25% of the general pop-
ulation has a patent foramen ovale that may open during
increased thoracic pressure. Transpulmonary passage of
microemboli alternatively may be attributed to elevated
pulmonary pressure.23 Using TCD technology (Emex-25;
Hatteland Instrumentering, Royken, Sweden) in patients
with renal replacement therapy, Forsberg et al9 demon-
strated that microemboli, developed during chronic he-
modialysis, passed the lung barrier and could be detected
in the carotid arteries. However, transmission of micro-
emboli from the venous circulation to the cerebral cir-
culation could not be conﬁrmed in a study by George
et al24 that used another TCD technology (Spencer
Technologies, Seattle, WA) for monitoring of CME in the
MCAs. However, this ﬁnding was surprising as the au-
thors expected detection of CME at least in the patients
with open foramen ovale. Both studies are not absolutely
contradictory, revealing that microemboli were generated
in hemodialysis circuits. Clearly, more scientiﬁc data are
needed to clarify in which cases microemboli are trans-
mitted to the brain.24
Gaseous and Solid CME in the MCAs
In our study the highest gaseous CME burden was
detected during activated CVVHD. This ﬁnding is in
agreement with the study by Forsberg et al9 who provided
ﬁrst evidence of the transmission of microemboli gen-
erated during hemodialysis to the cerebral circulation. As
an unexpected ﬁnding we also observed a lower but sig-
niﬁcant count of gaseous CME during the CVVHD-free
interval. Possible explanations for this interesting ﬁnding
include atherosclerotic disease (eg, carotids and proximal
aorta) and stagnant or turbulent blood ﬂow (eg, valvular
heart disease, intracranial vessel stenosis, presence of
intravascular catheters, or intravenous ﬂuid therapy
in critically ill patients).25–28 Therefore, we decided to
include a further control group consisting of non-ICU
FIGURE 1. Multifrequency-pulsed TCD technology. This technology uses real-time software to detect high-intensity transient
signals and can differentiate between solid and gaseous CME. The small light spots in the Doppler signal represent solid CME;
gaseous CME cannot be identified visually. CME indicates cerebral microemboli; MCA, middle cerebral artery; TCD, transcranial
Doppler ultrasound.
TABLE 1. Patients’ Demographic and Procedural Data
ICU Group
(n=20)
Non-ICU Group
(n=20)
Age (median [IQR]) (y) 55 (48-66) 69 (57-75)
Female, male (n) 6, 14 12, 8
Reason for admission (n [%])
Orthopedic surgery 0 (0) 20 (100)
Abdominal/vascular
surgery
6 (30) NA
Cardiac /thoracic surgery 4 (20) NA
Lung/liver transplant 5 (25) NA
Respiratory failure 3 (15) NA
Sepsis 2 (10) NA
Indication for CVVHD (n [%])
Acute renal failure 14 (70) NA
Chronic renal failure 6 (30) NA
Mechanical ventilation (n
[%])
12 (60) NA
SAPS3 (points) (median
[IQR])
49 (36-55) NA
Probability of death (median
[IQR])
12 (3-20) NA
Data are presented as median with IQRs (25th and 75th percentile), percent
(%), or number of observations (n).
CVVHD indicates continuous venovenous hemodialysis; ICU, intensive care
unit; IQR, interquartile range; NA, not applicable; SAPS3, simpliﬁed acute
physiology score.
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hospitalized orthopedic patients that did not require ICU
therapy and CVVHD treatment. Although a large body
of evidence shows that CME are frequently generated
during orthopedic surgery, no study has investigated
CME count before orthopedic surgery such as performed
in the present study. However, other research supports
the presence of CME in these cohorts of patients, as CME
frequently occur in elderly patients with atherosclerotic
aortic or carotid disease, or atrial ﬁbrillation. Recently, it
has been suggested that CME in elderly patients might
cause structural brain changes and cognitive decline likely
attributed to silent brain infarction.29
We also observed a higher solid CME count in the
ICU group during activated CVVHD than that during
the CVVHD-free interval, but this diﬀerence did not
reach signiﬁcance. A larger patient cohort might help
establish whether CVVHD also independently increases
patient solid CME burden. Although it has been pro-
posed that solid CME might cause more harm to the
brain than gaseous (and potentially dissolvable) CME,
this hypothesis remains unproven at present, as to the
best of our knowledge no studies have linked the quality
(gaseous vs. solid) of CME to the neurological outcomes
of critically ill patients. Both solid and gaseous CME in
theory may cause harm to the brain as shown in patients
undergoing cardiac surgery.30,31 Cerebral ischemia may
occur when the number of microemboli exceeds a
threshold CME count. Such a threshold for injury has not
been established but might presumably diﬀer between
individual patients and between numbers of gaseous or
solid CME.32 In summary, the research on CME evalu-
ation is a diﬃcult but emerging ﬁeld of study with po-
tential links to silent brain infarctions associated with
premature cerebral dysfunction, including dementia.33–36
Technological Considerations
There have been numerous investigations into the
underlying principle for CME diﬀerentiation and its
sensitivity and speciﬁcity.12,15,37,38 Currently, TCD de-
vices are rapidly increasing their diagnostic accuracy in
diﬀerentiating between gaseous and solid CME and re-
jecting artifacts. Although the utilization of 2 diﬀerent
ultrasound frequencies allows TCD studies to be con-
ducted with unprecedented accuracy.14 Together with the
increasing number of reported neuroimaging and clinical
studies related to CME evaluation, evidence is accruing
that CME eﬀectively represent Doppler-detectable cor-
relates of microemboli.20,38–41 Thus, the technique used in
the present study for CME detection and diﬀerentiation
seems reliable.42
Study Limitations
One major limitation of this observational pilot
study is the evaluation of a small patient cohort. Patients
in the ICU typically have various surgical circumstances
and medical diseases that might have potentially biased
our results. Additional study confounders include anti-
coagulation, ﬂuid therapy, hemodynamic state, and
mechanical ventilation. We did not change patient posi-
tioning or treatment during TCD examinations in an at-
tempt to best maintain steady state conditions. Ideally,
however, it would have been beneﬁcial to measure CME
in a randomized fashion and also in the CVVHD circuit
outlet to determine and correlate the number of micro-
emboli that entered the venous circulation. Although
diﬀerentiation between gaseous and solid CME can
be performed accurately, technological algorithms can be
false positive or negative in a few cases.12 Future CME
studies should also consider ruling out the presence of an
open foramen ovale. Although it was not incorporated
into the present observational pilot trial, it would be ad-
vantageous to link patient CME burden to the modern
neuroimaging evidence of silent brain infarction.
Such studies would allow for the direct correlation of
CME with morphologic signs of brain injury, thereby
providing important information in support of the
clinical signiﬁcance of the present study’s ﬁndings.
Overall, the current ﬁndings should be regarded as
representing a scientiﬁc perspective that needs further
investigation and conﬁrmation, and caution should be
A B
FIGURE 2. Gaseous and solid CME detection. The number of gaseous (A) and solid (B) CME detected with TCD per 30 minutes in
both middle cerebral arteries in non-ICU patients (n = 20) and in ICU patients (n = 20) measured during CVVHD and CVVHD-free
time interval (no CVVHD). CVVHD was associated with a higher burden of gaseous but not solid CME than those during CVVHD-
free interval in critically ill patients. CME indicates cerebral microemboli; CVVHD, continuous venovenous hemodialysis; ICU,
intensive care unit; HITS, high-intensity transient signals; TCD, transcranial Doppler ultrasound.
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taken in extrapolating this evidence into clinical practice.
We further would like to point out that it remains un-
known and highly debated if gaseous or solid CME cause
any brain injury at all.
CONCLUSIONS
This observational pilot study in critically ill pa-
tients demonstrated that activated CVVHD is associated
with a higher gaseous CME burden. There were no
diﬀerences in gaseous or solid CME counts between
critically ill patients during deactivated CVVHD and a
non-ICU control group of hospitalized patients before
elective orthopedic surgery. These ﬁndings suggest that
ICU therapy alone might not necessarily promote a
higher CME count, but activated CVVHD might sig-
niﬁcantly increase CME burden in critically ill patients.
The technology of automatic diﬀerentiation between
gaseous and solid CME is challenging and the impact of
the nature of CME on cerebral integrity remains un-
known. However, this emerging ﬁeld of silent brain in-
farction attributed to CME should be further investigated
due to potentially high clinical relevance.
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